1.
Zhonghua Jie He He Hu Xi Za Zhi
; 46(6): 619-624, 2023 Jun 12.
Artículo
en Chino
| MEDLINE
| ID: mdl-37278180
RESUMEN
Antimicrobial resistance in Mycobacterium tuberculosis is a serious threat to global tuberculosis(TB) control. WHO listed bedaquiline as one of the first-choice drugs for the treatment of MDR/RR-TB in 2018. Bedaquiline is marketed for adult patients with MDR-TB and XDR-TB. However, there are few studies of bedaquiline in adolescents, pregnant women, the elderly, and other special populations with drug-resistant TB. This paper aimed to review the effectiveness and safety of bedaquiline in the treatment of special populations of drug-resistant TB for the clinical use.
Asunto(s)
Tuberculosis Extensivamente Resistente a Drogas , Mycobacterium tuberculosis , Tuberculosis Resistente a Múltiples Medicamentos , Adolescente , Adulto , Anciano , Femenino , Humanos , Embarazo , Antituberculosos/efectos adversos , Diarilquinolinas/efectos adversos , Tuberculosis Extensivamente Resistente a Drogas/tratamiento farmacológico , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico
2.
Zhonghua Jie He He Hu Xi Za Zhi
; 44(3): 252-257, 2021 Mar 12.
Artículo
en Chino
| MEDLINE
| ID: mdl-33721939